Switch theme
Sign up to access all valuation multiples
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
1989
93
LTM Revenue $48.7M
Last FY EBITDA -$6.9M
$13.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Iridex has a last 12-month revenue (LTM) of $48.7M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Iridex achieved revenue of $48.7M and an EBITDA of -$6.9M.
Iridex expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Iridex valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $48.7M | XXX | $48.7M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $19.5M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 40% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$6.9M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -14% | XXX | XXX | XXX |
| EBIT | n/a | XXX | -$8.3M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | -17% | XXX | XXX | XXX |
| Net Profit | -$8.9M | XXX | -$8.9M | XXX | XXX | XXX |
| Net Margin | -18% | XXX | -18% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $0.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Iridex's stock price is $1.
Iridex has current market cap of $15.1M, and EV of $13.2M.
See Iridex trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $13.2M | $15.1M | XXX | XXX | XXX | XXX | $-0.54 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Iridex has market cap of $15.1M and EV of $13.2M.
Iridex's trades at 0.3x EV/Revenue multiple, and -1.9x EV/EBITDA.
Equity research analysts estimate Iridex's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Iridex has a P/E ratio of -1.7x.
See valuation multiples for Iridex and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $15.1M | XXX | $15.1M | XXX | XXX | XXX |
| EV (current) | $13.2M | XXX | $13.2M | XXX | XXX | XXX |
| EV/Revenue | 0.3x | XXX | 0.3x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -1.9x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -1.6x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.7x | XXX | -1.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialIridex's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.
Iridex's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Iridex's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Iridex and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -14% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 26% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 11% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 57% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Iridex acquired XXX companies to date.
Last acquisition by Iridex was XXXXXXXX, XXXXX XXXXX XXXXXX . Iridex acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Iridex founded? | Iridex was founded in 1989. |
| Where is Iridex headquartered? | Iridex is headquartered in United States of America. |
| How many employees does Iridex have? | As of today, Iridex has 93 employees. |
| Who is the CEO of Iridex? | Iridex's CEO is Mr. Patrick Mercer. |
| Is Iridex publicy listed? | Yes, Iridex is a public company listed on NAS. |
| What is the stock symbol of Iridex? | Iridex trades under IRIX ticker. |
| When did Iridex go public? | Iridex went public in 1996. |
| Who are competitors of Iridex? | Similar companies to Iridex include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Iridex? | Iridex's current market cap is $15.1M |
| What is the current revenue of Iridex? | Iridex's last 12 months revenue is $48.7M. |
| What is the current EV/Revenue multiple of Iridex? | Current revenue multiple of Iridex is 0.3x. |
| Is Iridex profitable? | Yes, Iridex is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
